Laura J. Hamill

Laura J. Hamill has been a member of our Board of Directors since June 2020. Ms. Hamill has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions. Most recently Ms. Hamill served as Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences, Inc., where she was accountable for 2,200 employees, $22 billion in annual revenue and led the commercial strategy and long-term planning. As a member of the executive team, she contributed to the corporate strategy and governance. Ms. Hamill also held a number of U.S. and international executive roles at Amgen, Inc., over an 18-year career with her last role being Senior Vice President US Commercial Operations, managing 2,000 employees across all Amgen’s therapeutic areas with annual revenue of $20 billion. Ms. Hamill’s areas of therapeutic expertise include inflammation, oncology, gene therapy, nephrology, osteoporosis, cardiovascular disease, migraine, HIV, hepatology, GI and anti-infectives. Ms. Hamill currently serves on the board of directors of AnaptysBio, Inc., (Nasdaq: ANAB), Pardes Biosciences, Inc. (Nasdaq: PRDS) BB Biotech AG, (a Swiss public listed company) and Scilex Holding Company (Nasdaq: SCLX). Ms. Hamill also is a board member for Unchained Labs, a private company. Ms. Hamill previously served on the board of Acceleron Pharma Inc. Ms. Hamill holds a B.A. in business administration from the University of Arizona.